Melbourne Startup Elita Raises $1.9M to Extend Dogs’ Healthy Lives
Melbourne pet-health startup Elita has raised $1.9 million in an early-stage funding round to expand its technology aimed at helping dogs live healthier lives for longer. The round was led by US-based Boost VC, with backing from Gandel Invest, Artesian, Touch Ventures and M8 Ventures.
The company, founded by Paloma Newton and Jackson Gritching, is moving beyond its original focus on pet cell banking toward a broader preventative healthcare platform. Its Elita Blueprint product brings together veterinary records, biological information and observations from owners to build a more complete picture of a dog’s health.
From Cell Banking to Preventative Care
Elita originally built its business around storing biological material from pets for potential future use. The startup has since expanded its focus toward monitoring a dog's health over time and helping owners identify changes before they become more serious.
Its platform is designed to bring information that is normally scattered across veterinary visits, laboratory results and an owner's own observations into one place. The company says this can give owners and vets a clearer view of how a dog's health changes over time.
New Funding Supports Platform Expansion
Elita plans to use the new capital to continue developing its technology and expand its presence in the pet-health market. The company is targeting a broader model of preventative care rather than relying only on treatment after a health problem appears.
The startup has also introduced 24/7 veterinary telehealth in Australia through a partnership with VetChat. Owners can connect with registered veterinarians through the platform, with the consultation supported by the dog's existing health information.
Elita Targets the Pet Longevity Market
The company is entering a growing market built around preventative pet healthcare and animal longevity. Elita's approach combines digital health records with biological information and veterinary support rather than focusing on a single treatment or diagnostic product.
Its longer-term ambition is to build a large-scale pet healthcare platform centred on extending the period of good health for dogs. That remains a developing market, and the effectiveness of individual longevity interventions will depend on clinical evidence and veterinary assessment.
Startup Plans to Build a Broader Health Platform
The latest funding gives Elita room to expand beyond its initial products and develop additional health-monitoring capabilities. The company says at-home biological testing is also planned as part of its next stage of development.
For Elita, the goal is to shift pet care toward earlier detection and preventative action. Whether that approach can translate into measurably longer and healthier lives for dogs will depend on how the platform's biological data, veterinary services and future products perform as the company scales.
